Evidence map›Paper›PMID 31126859›Full record

ArticleVaccine2019

Seroprevalence and durability of rubella virus antibodies in a highly immunized population.

Stephen N Crooke, Iana H Haralambieva, Diane E Grill, Inna G Ovsyannikova, Richard B Kennedy, Gregory A Poland

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Rubella Serosurvey Among Future Healthcare Workers.Frontiers in public health · 2021
    Article
  13. Article
  14. Article
  15. Rubella Immunity among Italian Female Healthcare Workers: A Serological Study.International journal of environmental research and public health · 2020
    Article
  16. Article
  17. Current Challenges in Vaccinology.Frontiers in immunology · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Stephen N CrookeMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Iana H HaralambievaMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Diane E GrillDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA.
Inna G OvsyannikovaMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Richard B KennedyMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Gregory A PolandMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: poland.gregory@mayo.edu.
Mayo Clinic in Florida · USMayo Clinic · USMayo Clinic in Arizona · US

Funding

Immunogenetic Mechanisms of Vaccine ResponseR37AI048793 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 2011 to 2020
$5.4M
IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSER01AI048793 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 2001 to 2010
$4.3M
NIAID NIH HHS R01 AI048793NIAID NIH HHS R37 AI048793
6 · The paper itself

Abstract

backgroundAlthough the administration of the measles-mumps-rubella (MMR) vaccine has been widespread in the United States for decades, gaps in vaccine coverage still persist for various reasons. The maintenance of herd immunity against rubella virus (RV) is important to controlling the spread and resurgence of rubella and congenital rubella syndrome.

methodsIn this study, we sought to assess the seroprevalence of RV-specific antibodies in an adult population from a defined geographic area in Olmsted County, MN, and the surrounding municipalities, with relatively high vaccine coverage and no documented evidence of circulating RV in the past 24 years. Rubella-specific IgG antibodies were measured by ELISA in a large set of serum samples (n = 1393) obtained from the Mayo Clinic Biobank. This cohort was 80.2% female and ranged from 20 to 44 years of age.

resultsIn total, 97.8% of subjects were seropositive for rubella-specific IgG antibodies, with a median titer of 40.56 IU/mL, suggesting a high degree of immunization; however, 2.2% of subjects were found to be seronegative. Interestingly, 25.1% of subjects were seropositive but had titers lower than 25 IU/mL, indicating either a population of low responders or individuals that could potentially be at risk of waning immunity. No significant associations or differences were found between RV-specific titers and demographic variables such as age, sex, or body mass index (BMI).

conclusionsA high rate of seropositivity for rubella was found among this young adult cohort, but a significant percent of the cohort had lower titers that may indicate poor initial vaccine response and potential risk if their antibody titers decline.

Indexed as

AdultAntibodies, ViralCohort StudiesFemaleHumansImmunizationImmunization ScheduleImmunoglobulin GMaleMeasles-Mumps-Rubella VaccineRubellaRubella virusSeroepidemiologic StudiesYoung AdultAntibodies, ViralImmunoglobulin GMeasles-Mumps-Rubella Vaccinerubella antibodiesAntibodiesDemographicsMeasles-mumps-rubellaMMRRubellaSeroepidemiologyTiter

Identifiers

PMID31126859
PMCPMC6934099
OpenAlexW2945210534

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.